Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 PK, Safety and Tolerability Study of KT07 (Lianhua Qingwen) in Healthy Adults
NCT05223660Phase 1Completed
- Sponsor
- Yiling Pharmaceutical
- Start
- Jan 2022
- Primary completion
- Jul 2022
- Modality
- HM (Herbal Medicine)
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of Lianhua Qingwen in coronavirus disease 2019 (COVID-19) and influenza (5 arms), sponsored by Yiling Pharmaceutical. Primary endpoints: Area Under the Curve from time 0 to time t at 13 days, Area Under the Curve from time 0 to infinity at 13 days and 6 more. Started Jan 2022; status: completed.
02
Drugs
Lianhua Qingwen
03
Conditions
coronavirus disease 2019 (COVID-19)influenza
Beyond the preview
Go deeper on NCT05223660.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05223660.